Moving Forward after Major Stroke Trial: Endovascular Care for Some; More Research on Tap

Share

Joseph Broderick, MD, international stroke expert and Research Director of UCNI.
Photo by Mark Bowen Media.

Joseph Broderick, MD, Research Director at the UC Neuroscience Institute, was in the spotlight last week as the Principal Investigator of an international clinical trial that compared outcomes of stroke patients who received a clot-dissolving drug (tPA) through an IV and those who also received endovascular therapy. The endovascular treatment involved either delivering tPA directly to the clot via a catheter threaded up from the groin to the brain, or using a catheter and an FDA-approved device to actually retrieve the clot.

The clinical trial, the Interventional Management of Stroke III (IMS III), found that patients who received the high-tech endovascular treatment fared no better than those who received tPA through an IV, although the safety of the two approaches was very similar. The trial disappointed stroke specialists who had sought to provide a new solution to the problem of stroke caused by a blockage in major arteries supplying oxygen-rich blood to the brain.

Dr. Broderick, the Albert Barnes Voorheis Professor and Chair of UC’s Department of Neurology and Rehabilitation Medicine, authored the study, which appeared in the New England Journal of Medicine. He discussed the study and its ramifications with multiple media outlets, including the New York Times, the Los Angeles Times and the Washington Post, at the International Stroke Conference 2013 last week in Honolulu.

The study will likely change how some stroke patients are treated at the UC Neuroscience Institute, one of four institutes of the UC College of Medicine and UC Health. The majority of patients will continue to be treated with tPA through an IV, without additional endovascular care.  However, a subset of patients — those with large clots in large arteries — will strongly be considered for treatment with endovascular methods.

“Our study found that patients who have occlusions of the distal internal carotid artery did poorly with IV tPA and better with an endovascular approach, although the number of patients in that particular subgroup was small,” Dr. Broderick said.

Stroke patients may also benefit from two additional developments. The first is the UC Stroke Team’s effort to start endovascular therapy sooner, so as to maximize its benefits. “We have made efforts to minimize the time to start endovascular therapy since patients treated earlier tended to do better,” Dr. Broderick said. “We need to do an even better job with this.”

Andrew Ringer, MD

The second development involves improvements in the clot-retrieval devices themselves. “I think the new generation of devices is clearly better in opening arteries than what we had for most of the IMS III study,” said Andrew Ringer, MD, Director of the Division of Cerebrovascular Surgery and Professor of Neurosurgery & Radiology at UC. “I’ve seen a big difference in my own cases.”

Dr. Ringer and his colleagues at the Endovascular Neurosurgery Research Group, whose 20-plus members include the Mayo Clinic, Cornell University and the University of California, San Diego, have collected data on the effectiveness of a new FDA-approved flow-restoration device known as the Solitaire. A multi-center retrospective analysis of the self-expanding stent retriever was recently accepted by a peer-reviewed neurosurgical journal.

Dr. Broderick agreed that the newer devices open arteries better than those studied in the IMS III trial. A lingering question, however, is whether these improvements “will translate into better clinical outcomes for patients compared to IV tPA or standard therapy in patients who are beyond the tPA treatment window of 3 to 4 ½ hours.”

Pooja Khatri, MD

One thing is certain: the UC Stroke Team will continue to be at the center of international research into the best methods for treating patients who suffer acute stroke. “We remain very eager to participate in trials that test the combined tPA/endovascular and IV tPA alone approaches,” Dr. Broderick said. “We are participating in the Therapy Trial, which uses one of the new stent-retriever devices as well as a device that aspirates the clot. “We are also working on our next trial designs to improve rapid opening of brain arteries in acute stroke. These trials will include a combination of medications and advances in new mechanical devices.”

Pooja Khatri, MD, Associate Professor of Neurology and a neurologist at the UC Neuroscience Institute, is the medical principal investigator for the Therapy Trial, a multi-site U.S. study.

–Cindy Starr

This entry was posted in UC Neuroscience Blog and tagged , , , , , , , . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • UCNI Weekly Blog
  • Join Our Email List
    for Bi-Monthly Updates

    Click here to continue.
  • Hope Stories

    • Alison’s Story: Ruptured Aneurysm following Neurotrauma

      Alison's Story: Ruptured Aneurysm following Neurotrauma She has completed medical school, has won the Flying Pig Marathon and has reached the summit of two of Colorado’s 14,000-foot peaks.Today Dr. Alison Delgado is tackling a mountain of a different kind. Step by hard-earned step, word by remembered...
    • Dale’s Hope Story: Parkinson’s

      Dale's Hope Story: Parkinson's [hana-flv-player video="/wp-content/videos/Dale_Ankeman_Sunflower_3.flv" width="500" height="377" description="" player="2" autoload="true" autoplay="false" loop="false" autorewind="true" /] After being diagnosed with Parkinson’s disease in 2003, 46-year-old Dale Ankenman was determined not to let it keep him off his bike. Considering his long list of credentials, including former...
    • Tim’s Story: Traumatic Brain Injury

      Tim's Story: Traumatic Brain Injury This story includes a graphic description of Tim’s traumatic brain injury. If you are squeamish or faint of heart, you may wish to close this file and turn to a different story of hope.   Tim was outdoors doing what he liked...
    • Charles Sabine’s Story: Huntington’s Disease

      Charles Sabine's Story: Huntington's DiseaseIn 2005 the NBC war correspondent Charles Sabine made the life-altering decision to face up to his family history of Huntington’s disease and undergo genetic testing. The odds, he knew, were 50-50 that he, too, had the gene and would...
    • Norma’s Story: Essential Tremor

      Norma's Story: Essential TremorQuestion: what progressive neurological condition causes a rhythmic trembling of the head, voice, legs or trunk; can be treated with medication or deep brain stimulation; has no definitive cure; and is eight times more common than Parkinson’s disease? If you’re...
    • Amber’s Story: Ruptured Aneurysm

      Amber's Story: Ruptured Aneurysm The only visible sign of Amber Gray’s ordeal is the long slender scar   that runs along her forearm. It is the area where a surgeon carefully   removed her radial artery, which was needed to bypass a damaged artery   in her...
    • Kevin’s Story: Acoustic Neuroma

      Kevin's Story: Acoustic Neuroma Kevin was in his mid-40s when he began to notice that he wasn’t hearing quite as well as in the past. But the change was gradual, so he didn’t worry about it. A few years went by, and the hearing...
    • Brian’s Story: Vocal Cord Cyst

      Brian's Story: Vocal Cord Cyst One by one, the symptoms of a throat problem tapped on the pastor’s door. Pastor Brian Tome, leader of Crossroads Church and speaker of five weekly messages to a following of 15,000, acknowledged the symptoms and tried to dismiss them....
    • Richard’s Story: Ruptured Aneurysms

      Richard's Story: Ruptured Aneurysms Almost three years ago, Richard “Dick” Watson, MD, found himself in an unfamiliar position for a doctor: lying on the operating table instead of standing over it. He didn’t know it at the time, but it was the beginning of...
    • Sandra’s Story Glioma

      Sandra's Story Glioma Sandra (Sandy) is a smiling, breathing reminder that hope exists for patients with even the most challenging type of brain tumors. Nine years ago, when Sandy was first told that she had six months to live, she stared back blankly...